Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services (NY: WST )

375.35 +3.31 (+0.89%)
Official Closing Price Updated: 7:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services

< Previous 1 2 3 4 5 6 7 Next >
Why the dividend investor may take a look at NYSE:WST.
Via Chartmill
(WST) - Analyzing West Pharmaceutical Servs's Short Interest
Via Benzinga
Exploring NYSE:WST's dividend characteristics.
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) is a Top Pick for Dividend Investors. 
Via Chartmill
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Analyzing NYSE:WST's Dividend Potential.
Is WEST PHARMACEUTICAL SERVICES (NYSE:WST) a Good Fit for Dividend Investing? 
Via Chartmill
S&P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What's Driving Markets Thursday?
US stocks surge on strong earnings and speculation of Fed rate cuts. S&P 500 rebounds past 5000, Nasdaq 100 pauses. Small caps outperform. Tesla, Wells Fargo, and CBRE rally on positive news while Deer... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
(WST) - Analyzing West Pharmaceutical Servs's Short Interest
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
West Pharmaceutical's 2024 Outlook Cautious, Analysts Remain Optimistic
West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth,... 
Via Benzinga
West Pharmaceutical Sets 2024 EPS Guidance at $7.50-$7.75
WST reported a robust fourth-quarter with net sales of $732.0 million, marking a 3.3% increase. 
Via Talk Markets
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a quality stock.
Why the quality investor may take a look at WEST PHARMACEUTICAL SERVICES (NYSE:WST). 
Via Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth $20,000 Today
Via Benzinga
Keybanc Maintains Overweight Rating for West Pharmaceutical Servs: Here's What You Need To Know
Via Benzinga
TransDigm, West Pharmaceutical, Thermo Fisher Scientific And A Tech Company On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Steve Weiss of Short Hills Capital Partners named TransDigm Group Incorporated (NYSE: TDG), which is scheduled to release 
Via Benzinga
Here's How Much You Would Have Made Owning West Pharmaceutical Servs Stock In The Last 10 Years
Via Benzinga
West Pharmaceutical Services Bullish Daily Cycle
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. 
Via Talk Markets
Here's How Much $100 Invested In West Pharmaceutical Servs 15 Years Ago Would Be Worth Today
Via Benzinga
How Is The Market Feeling About West Pharmaceutical Servs?
Via Benzinga
How Is The Market Feeling About West Pharmaceutical Servs?
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,300 Today
Via Benzinga
Looking Into West Pharmaceutical Servs's Recent Short Interest
Via Benzinga
Here's How Much $1000 Invested In West Pharmaceutical Servs 5 Years Ago Would Be Worth Today
Via Benzinga
Blue-Chip Bargains: Top 3 Oversold Aristocrats for Value Investors
These three oversold blue-chip stocks offer growth and long-term income while the stocks trade at attractive levels. 
Via InvestorPlace
3 Dividend Champions with room for dividend growth
Dividend Champions that have payout ratios below 20%, like these three stocks, can be an incredibly compelling choice for buy-and-hold dividend investors. 
Via MarketBeat
Sotera Health Appoints Karen Flynn to Board of Directors
From Sotera Health Services, LLC
Via GlobeNewswire
$100 Invested In West Pharmaceutical Servs 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.